In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India Groups Unite To Challenge Herceptin Breast Cancer Patent (India)

This article was originally published in PharmAsia News

Executive Summary

Groups in India are organizing to challenge the patent granted F. Hoffman-LaRoche for its Herceptin (trastuzumb) for fighting breast cancer. The challengers have formed the Lawyers Collective to fight for women's issues, arguing in this case that giving the drug patent protection denies millions of women with the cancer from having access to cheap versions. The same group challenged a Novartis application for a patent on its Gleevec (imatinib mesylate) in 2005, and litigation continues. (Click here for more

You may also be interested in...



Moderna Marches First Coronavirus Vaccine To US Test

The first vaccine for the new coronavirus has entered the clinic, with US firm Moderna leading the race.

SK Bio Begins New Coronavirus Vaccine Development Using Versatile Platform

Korean vaccine specialist SK Bioscience moves to develop versatile platform technology to deal with outbreaks of infectious diseases such as the new coronavirus, as the number of infections in the country surges.

QUOTED. 25 February 2020. David Maman.

Israel-based Binah.ai hopes to earn regulatory approval for a video-based monitoring app that can detect vital signs in minutes. See what Binah.ai's co-founder and CEO, David Maman, said about the technology here.   

UsernamePublicRestriction

Register

SC065869

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel